Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells $1,273,584.95 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 77,705 shares of Centessa Pharmaceuticals stock in a transaction on Monday, December 16th. The shares were sold at an average price of $16.39, for a total transaction of $1,273,584.95. Following the completion of the sale, the general counsel now directly owns 125,785 shares of the company’s stock, valued at approximately $2,061,616.15. This trade represents a 38.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Centessa Pharmaceuticals Trading Up 6.3 %

NASDAQ CNTA opened at $17.55 on Friday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $16.62 and a 200 day simple moving average of $13.51. Centessa Pharmaceuticals plc has a 12 month low of $6.65 and a 12 month high of $18.97. The firm has a market capitalization of $2.31 billion, a P/E ratio of -11.47 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. B. Riley started coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price for the company. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Jefferies Financial Group lifted their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Finally, BMO Capital Markets upped their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $25.83.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC boosted its position in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP grew its stake in Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP purchased a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter valued at $90,000. Finally, Fred Alger Management LLC bought a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth $99,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.